Barcelona Liver Bioservices (BLB) announced today the presentation of a poster introducing the BLB’s proprietary experimental model of nonalcoholic steatohepatitis (NASH) at the 42nd annual meeting of the Spanish Association for the Study of the Liver (AEEH), held in Madrid, Spain.
Barcelona Liver Bioservices (BLB) announced today a non-exclusive partnership with the biopharmaceutical company Gilead Sciences to characterize the effects of novel chemical entities developed by Gilead for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH).
Barcelona Liver Bioservices (BLB), CRO specialized in the design and development of pre-clinical research in hepatology, announced today a non-exclusive partnership with BrudyLab to explore Brudy’s lead compound DHA as novel therapeutic option for liver disease.
Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Conatus Pharmaceuticals, biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.
Barcelona Liver Bioservices (BLB), a spin-off of IDIBAPS, has been created for the design and development of pre-clinical studies in the fields of hepatology and hepatotoxicity. The co-founders are Jordi Gracia-Sancho, Jaume Bosch and Joan Carles Garcia-Pagan from IDIBAPS and Rosa Villa from CSIC.